Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

618

Participants

Timeline

Start Date

October 28, 2016

Primary Completion Date

May 29, 2018

Study Completion Date

December 31, 2025

Conditions
Infection, Human Immunodeficiency VirusHIV Infections
Interventions
DRUG

Cabotegravir (CAB) tablet

It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat

DRUG

Rilpivirine (RPV) tablet

"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose"

DRUG

Cabotegravir - Injectable Suspension (CAB LA)

It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection

DRUG

Rilpivirine - Injectable Suspension (RPV LA)

It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.

DRUG

2 NRTIs plus an INI, NNRTI, or PI

"Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus:~* INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen)~* NNRTI (either the initial or second cART regimen)~* Boosted PI (or atazanavir \[ATV\] unboosted) (either the initial or second PI-based cART regimen)"

Trial Locations (113)

1055

GSK Investigational Site, Middelburg

1141

GSK Investigational Site, Buenos Aires

1427

GSK Investigational Site, Buenos Aires

2000

GSK Investigational Site, Rosario

2010

GSK Investigational Site, Darlinghurst

GSK Investigational Site, Sydney

2113

GSK Investigational Site, Johannesburg

3181

GSK Investigational Site, Prahran

4001

GSK Investigational Site, Durban

4052

GSK Investigational Site, Durban

7925

GSK Investigational Site, Cape Town

9301

GSK Investigational Site, Bloemfontein

9400

GSK Investigational Site, Winnie Mandela

10016

GSK Investigational Site, New York

10029

GSK Investigational Site, New York

10439

GSK Investigational Site, Berlin

10787

GSK Investigational Site, Berlin

14004

GSK Investigational Site, Córdoba

14201

GSK Investigational Site, Buffalo

15212

GSK Investigational Site, Pittsburgh

15706

GSK Investigational Site, Santiago de Compostela

18102

GSK Investigational Site, Allentown

20007

GSK Investigational Site, Washington D.C.

20009

GSK Investigational Site, Washington D.C.

20037

GSK Investigational Site, Washington D.C.

20146

GSK Investigational Site, Hamburg

20157

GSK Investigational Site, Milan

20246

GSK Investigational Site, Hamburg

22003

GSK Investigational Site, Annandale

24501

GSK Investigational Site, Lynchburg

25123

GSK Investigational Site, Brescia

28034

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

28209

GSK Investigational Site, Charlotte

29010

GSK Investigational Site, Málaga

30625

GSK Investigational Site, Hanover

31059

GSK Investigational Site, Toulouse

31201

GSK Investigational Site, Macon

32960

GSK Investigational Site, Vero Beach

33316

GSK Investigational Site, Fort Lauderdale

34237

GSK Investigational Site, Sarasota

34295

GSK Investigational Site, Montpellier

34982

GSK Investigational Site, Ft. Pierce

35015

GSK Investigational Site, Daejeon

35294

GSK Investigational Site, Birmingham

36312

GSK Investigational Site, Vigo Pontevedra

41013

GSK Investigational Site, Seville

41944

GSK Investigational Site, Daegu

44280

GSK Investigational Site, Guadalajara

45122

GSK Investigational Site, Essen

46014

GSK Investigational Site, Valencia

48202

GSK Investigational Site, Detroit

49241

GSK Investigational Site, Pusan

53127

GSK Investigational Site, Bonn

59208

GSK Investigational Site, Tourcoing

60590

GSK Investigational Site, Frankfurt

60596

GSK Investigational Site, Frankfurt

60611

GSK Investigational Site, Chicago

63110

GSK Investigational Site, St Louis

68198

GSK Investigational Site, Omaha

75018

GSK Investigational Site, Paris

75246

GSK Investigational Site, Dallas

75475

GSK Investigational Site, Paris

75571

GSK Investigational Site, Paris

75651

GSK Investigational Site, Paris

77098

GSK Investigational Site, Houston

78705

GSK Investigational Site, Austin

80246

GSK Investigational Site, Denver

80335

GSK Investigational Site, München

85015

GSK Investigational Site, Phoenix

90036

GSK Investigational Site, Los Angeles

90069

GSK Investigational Site, Los Angeles

90813

GSK Investigational Site, Long Beach

92264

GSK Investigational Site, Palm Springs

93205

GSK Investigational Site, Saint-Denis

93301

GSK Investigational Site, Bakersfield

94109

GSK Investigational Site, San Francisco

94110

GSK Investigational Site, San Francisco

105275

GSK Investigational Site, Moscow

190103

GSK Investigational Site, Saint Petersburg

193167

GSK Investigational Site, Saint Petersburg

196645

GSK Investigational Site, Saint Petersburg

214006

GSK Investigational Site, Smolensk

302040

GSK Investigational Site, Oryol

350015

GSK Investigational Site, Krasnodar

398043

GSK Investigational Site, Lipetsk

410009

GSK Investigational Site, Saratov

420061

GSK Investigational Site, Kazan'

445846

GSK Investigational Site, Toliyatti

620102

GSK Investigational Site, Yekaterinburg

650056

GSK Investigational Site, Kemerovo

02129

GSK Investigational Site, Boston

27599-7064

GSK Investigational Site, Chapel Hill

45267-0405

GSK Investigational Site, Cincinnati

C1405CKC

GSK Investigational Site, Ciudad Autonoma de Bueno

K1H 8L6

GSK Investigational Site, Ottawa

M5G 1K2

GSK Investigational Site, Toronto

H2L 4E9

GSK Investigational Site, Montreal

H4A 3J1

GSK Investigational Site, Montreal

G1V 4G2

GSK Investigational Site, Québec

S4P 0W5

GSK Investigational Site, Regina

0087

GSK Investigational Site, Pretorai

03722

GSK Investigational Site, Seoul

06591

GSK Investigational Site, Seoul

08916

GSK Investigational Site, Badalona

08003

GSK Investigational Site, Barcelona

08035

GSK Investigational Site, Barcelona

08036

GSK Investigational Site, Barcelona

03203

GSK Investigational Site, Elche Alicante

SE-416 85

GSK Investigational Site, Gothenburg

SE-118 83

GSK Investigational Site, Stockholm

SE-14186

GSK Investigational Site, Stockholm

Sponsors
All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY